Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to compare the liquid suspension form of AZD 2624 to a tablet form of the same drug. This study will also study the effect of food on the tablet form of the drug.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment A | Experimental | Single oral dose of 40 mg AZD2624 liquid suspension in a fasted state. |
|
| Treatment B | Experimental | Single oral dose of 40 mg (2x20mg tablets)AZD2624 in a fasted state. |
|
| Treatment C | Experimental | Single oral dose of 40 mg (2x20mg tablets) in a fed state. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AZD2624 | Drug | Single dose of 40 mg AZD2624 liquid suspension, PO |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Serial blood draws will be used to measure the plasma levels of AZD2624 for the liquid suspension and the tablet formulation in a fed and fasted state. | Seventeen blood draws will be collected during each treatment period for a total of 51 samples for the study. |
| Measure | Description | Time Frame |
|---|---|---|
| Safety will be measured by the collection of AEs, ECGs, physical exams, and vital signs. | Subjects inquiry on AE daily, ECGs collected at 2 timepoints each period, clinical labs collected at 3 timepoints each period, physical exams completed 3 timepoints each period, and vital signs collected each day of each period |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sylvan Hurewitz, MD | AstraZeneca Clinical Pharmacology Unit, US | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Philadelphia | Pennsylvania | United States |
Not provided
| ID | Term |
|---|---|
| C555357 | 3-((methylsulfonyl)amino)-2-phenyl-N-(1-phenylpropyl)quinolin-4-carboxamide |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| AZD2624 |
| Drug |
Single dose of 40 mg AZD 2624 (2x20mg tablets), PO |
|